Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	2.88M 2.48M 2.35M 2.13M 3.99M 275M 4.01M 27.86M 10.72M 140M 10.8M 10.56M 442M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-1.35M -1.16M -1.1M -998K -1.87M -129M -1.88M -13.07M -5.03M -65.58M -5.07M -4.96M -207M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

26/08	Scisparc Ltd. Announces Appointment of Prof. Carmel Domshlak to Scientific Advisory Board for Ai and Cybersecurity, Effective September 1, 2026	CI
17/08	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.	CI
05/08	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome	CI
29/07	Scisparc Ltd. Announces Establishment of Scientific Advisory Board	CI
30/06	Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding from SciSparc Ltd.	CI
30/04	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
29/04	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
17/03	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
17/03	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
10/03	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
10/03	Top Premarket Decliners	MT
12/02	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
26/01	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI

02/09	SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies	GL
01/09	SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial	GL
26/08	SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board	GL
24/08	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation	GL
19/08	SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)	PU

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	10/01/2022
Amitay Weiss CEO	Chief Executive Officer	62	21/08/2020
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	08/02/2016

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	10/01/2022
Itschak Shrem CHM	Chairman	79	21/09/2025
Lior Vider BRD	Director/Board Member	50	21/08/2020

SciSparc Ltd. Stock OTC Markets

Stocks

TRPXD

US80909J1025

Pharmaceuticals

Valuation : SciSparc Ltd.

Latest news : SciSparc Ltd.

Press Releases : SciSparc Ltd.

News in other languages : SciSparc Ltd.

Quotes and Performance

Managers and Directors : SciSparc Ltd.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/6/26	Itschak Shrem	Sell	Chairman	-462	0.0806%
18/3/26	Amnon Ben Shay	Other	Director	3,652	0.0839%
18/3/26	Oz Adler	Other	Chief Executive Officer	11,064	0.2543%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCISPARC LTD.	-19.03%	-15.79%	-	-	2.88M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.13%	-3.97%	+15.48%	+62.77%	46.7B
OTSUKA HOLDINGS CO., LTD.	-1.13%	-7.39%	+36.30%	+109.40%	39.11B
ZYDUS LIFESCIENCES LIMITED	+0.12%	-2.09%	+7.65%	+78.16%	11.66B
CIPLA LIMITED	-0.53%	-2.06%	-12.65%	+9.75%	11.6B
KRKA, D. D.	-0.38%	0.00%	+19.82%	+136.36%	9.19B
GEDEON RICHTER	+0.32%	-2.26%	+23.33%	+33.23%	7.27B
GLENMARK PHARMACEUTICALS LIMITED	+0.17%	-1.62%	+13.53%	+211.41%	7.13B
ONO PHARMACEUTICAL CO., LTD.	-1.00%	-6.83%	+33.22%	-17.14%	7.15B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-3.13%	-4.45%	-45.09%	+17.23%	5.13B
Average	-2.60%	-3.09%	+10.18%	+71.24%	16.1B
Weighted average by Cap.	-0.88%	-3.63%	+17.52%	+77.29%

	2024	2025
Net sales	1.31 1.13 1.07 0.97 1.81 124.77 1.82 12.65 4.87 63.48 4.9 4.8 200.58	0.86 0.74 0.7 0.63 1.19 81.78 1.19 8.29 3.19 41.61 3.21 3.14 131.47
Net income	-6.28M -5.41M -5.13M -4.65M -8.72M -600M -8.76M -60.89M -23.41M -305M -23.6M -23.08M -965M	-12.18M -10.49M -9.94M -9.01M -16.9M -1.16B -16.98M -118M -45.38M -592M -45.74M -44.74M -1.87B
Net Debt	-2.01M -1.73M -1.64M -1.49M -2.79M -192M -2.8M -19.49M -7.49M -97.74M -7.55M -7.39M -309M	-4.22M -3.64M -3.45M -3.12M -5.86M -404M -5.89M -40.94M -15.74M -205M -15.87M -15.52M -649M